CAS Number54739-18-3
Synonyms2-{[(E)-{5-Methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene}amino]oxy}ethanamine; (E)-5-Methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone O-(2-Aminoethyl)oxime; Faverin; Floxyfral; Dumirox; Maveral; 5-methoxy-1-[4-(trifluoromethyl)-phenyl]-1-pentanone-0-(2-aminoethyl)oxime; 2-[({(1E)-5-Methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene}amino)oxy]ethanamine; Luvox; MFCD00865345; 5-methoxy-1-[4-(trifluoromethyl)-phenyl]-1-pentanone O-(2-aminoethyl)oxime; Fevarin; 2-[[5-methoxy-1-[4-(trifluoromethyl)phenyl]-pentylidene]amino]oxyethanamine; (1E)-5-Methoxy-1-[4-(trifluoromethyl)phenyl]pentanal O-(2-aminoethyl)oxime; 5-Methoxy-4'-(trifluoromethyl)valerophenone (E)-O-(2-aminoethyl)oxime; Fluvoxamine; (E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanoneo-(2-aminoethyl)oxime
Molecular FormulaC15H21O2N2F3
Molecular Weight318.34
Purity98%
Density1.2±0.1 g/cm3
Boiling Point370.6±52.0 °C at 760 mmHg
Melting Point120-122.5ºC
AppearanceTransparent colorless oil
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 54739-18-3 |
| Catalog No. | 2A-9010594 |
| Chinese Name | 氟伏沙明 |
| Synonyms | 2-{[(E)-{5-Methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene}amino]oxy}ethanamine; (E)-5-Methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone O-(2-Aminoethyl)oxime; Faverin; Floxyfral; Dumirox; Maveral; 5-methoxy-1-[4-(trifluoromethyl)-phenyl]-1-pentanone-0-(2-aminoethyl)oxime; 2-[({(1E)-5-Methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene}amino)oxy]ethanamine; Luvox; MFCD00865345; 5-methoxy-1-[4-(trifluoromethyl)-phenyl]-1-pentanone O-(2-aminoethyl)oxime; Fevarin; 2-[[5-methoxy-1-[4-(trifluoromethyl)phenyl]-pentylidene]amino]oxyethanamine; (1E)-5-Methoxy-1-[4-(trifluoromethyl)phenyl]pentanal O-(2-aminoethyl)oxime; 5-Methoxy-4'-(trifluoromethyl)valerophenone (E)-O-(2-aminoethyl)oxime; Fluvoxamine; (E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanoneo-(2-aminoethyl)oxime |
| Molecular Formula | C15H21O2N2F3 |
| Molecular Weight | 318.34 |
| Purity | 98 |
| Density | 1.2±0.1 g/cm3 |
| Boiling Point | 370.6±52.0 °C at 760 mmHg |
| Melting Point | 120-122.5ºC |
| Appearance | Transparent colorless oil |
| Storage Condition | -20°C Freezer, Under Inert Atmosphere |
| Application | Fluvoxamine is a serotonin reuptake inhibitor with antidepressant activity. |
| HTC | 2928000090 |
| MDL Number | MFCD11978014 |
| SMILES | COCCCCC(=NOCCN)c1ccc(C(F)(F)F)cc1 |
| InChI | InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+ |
| InChI Key | CJOFXWAVKWHTFT-XSFVSMFZSA-N |
| MSDS | msds/10594_1_54739_18_3.pdf |
| Use of | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor.Target: SSRIsFluvoxamine is effective in inhibiting 5-ht uptake by blood platelets and brain synaptosomes. The antagonism by fluvoxamine of the reserpine-induced lowering of the pentamethylenetetrazole convulsive threshold can be regarded as due to an effect upon 5-HT uptake. In contrast to the effects of desmethylimipramine and imipramine, no stimulatory effects are found in rats when rapidly acting reserpine-like compounds are given following a dose of fluvoxamine [1]. fluvoxamine appears to improve combat-related PTSD symptoms but not depressive symptoms. The high attrition rate and lack of a placebo group limits the conclusions of our study. Controlled studies of fluvoxamine in the treatment of PTSD are warranted [2]. Fluvoxamine was less potent at decreasing ethanol self-administration when food was available concurrently versus when ethanol was available in isolation [ED50: 4.0 (2.7-5.9) and 5.1 (4.3-6.0)]. Effects on food were similar under each condition in which food was available. The results demonstrate that the potency of fluvoxamine in reducing ethanol-maintained behavior depends on whether ethanol is available in isolation or in the context of concurrently scheduled food reinforcement [3].Clinical indications: Depression; Obsessive compulsive disorder; Social phobia FDA Approved Date: December 5, 1994Toxicity: Anorexia, Constipation, Dry mouth, Headache, Nausea, Nervousness, Skin rash, Sleep problems, Somnolence, Liver toxicity, Mania, Increase urination, Seizures, Sweating increase, Tremors, or Tourette's syndrome. Properties Name fluvoxamine Synonym More Synonyms Fluvoxamine Biological Activity Description Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor.Target: SSRIsFluvoxamine is effective in inhibiting 5-ht uptake by blood platelets and brain synaptosomes. The antagonism by fluvoxamine of the reserpine-induced lowering of the pentamethylenetetrazole convulsive threshold can be regarded as due to an effect upon 5-HT uptake. In contrast to the effects of desmethylimipramine and imipramine, no stimulatory effects are found in rats when rapidly acting reserpine-like compounds are given following a dose of fluvoxamine [1]. fluvoxamine appears to improve combat-related PTSD symptoms but not depressive symptoms. The high attrition rate and lack of a placebo group limits the conclusions of our study. Controlled studies of fluvoxamine in the treatment of PTSD are warranted [2]. Fluvoxamine was less potent at decreasing ethanol self-administration when food was available concurrently versus when ethanol was available in isolation [ED50: 4.0 (2.7-5.9) and 5.1 (4.3-6.0)]. Effects on food were similar under each condition in which food was available. The results demonstrate that the potency of fluvoxamine in reducing ethanol-maintained behavior depends on whether ethanol is available in isolation or in the context of concurrently scheduled food reinforcement [3].Clinical indications: Depression; Obsessive compulsive disorder; Social phobia FDA Approved Date: December 5, 1994Toxicity: Anorexia, Constipation, Dry mouth, Headache, Nausea, Nervousness, Skin rash, Sleep problems, Somnolence, Liver toxicity, Mania, Increase urination, Seizures, Sweating increase, Tremors, or Tourette's syndrome. Related Catalog Signaling Pathways >> Neuronal Signaling >> Serotonin Transporter Research Areas >> Neurological Disease Natural Products >> Alkaloid References [1]. Escalona, R., et al., Fluvoxamine treatment in veterans with combat-related post-traumatic stress disorder. Depress Anxiety, 2002. 15(1): p. 29-33. [2]. Ginsburg, B.C., J.W. Pinkston, and R.J. Lamb, The potency of fluvoxamine to reduce ethanol self-administration decreases with concurrent availability of food. Behav Pharmacol, 2012. 23(2): p. 134-42. [3]. Claassen, V., et al., Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor. Br J Pharmacol, 1977. 60(4): p. 505-16. Chemical & Physical Properties Molecular Formula C15H21F3N2O2 Exact Mass 318.155518 PSA 56.84000 Index of Refraction 1.474 InChIKey CJOFXWAVKWHTFT-XSFVSMFZSA-N Safety Information HS Code 2928000090 |
| Tax Rebate | 9.0% |
| Supervision | none |
| Transport Info | Product name: Summary 2928000090 other organic derivatives of hydrazine or of hydroxylamine VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:20.0% |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Fluoxetine HCl; Fluoxetine hydrochloride | 56296-78-7 | 2A-9010571 |
| Fluphenazine | 69-23-8 | 2A-9010573 |
| Fluphenazine enanthate | 2A-301657 | 2A-9010574 |
| Fluvastatin | 93957-54-1 | 2A-9010592 |
| Fluvastatin sodium | 93957-55-2 | 2A-9010593 |
| Formoterol | 73573-87-2 | 2A-9010605 |
| Formoterol fumarate dihydrate | 2519-30-4 | 2A-9010606 |
| Fosinopril | 98048-97-6 | 2A-9010617 |
| Fosinopril sodium | 88889-14-9 | 2A-9010618 |
| Fosinoprilat | 95399-71-6 | 2A-9010619 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS